Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.75M Buy
778,252
+44,945
+6% +$271K ﹤0.01% 1968
2026
Q1
$4.52M Sell
733,307
-497,546
-40% -$4.13M 0.01% 1771
2025
Q4
$12.8M Buy
1,230,853
+1,075,563
+693% +$10.8M 0.01% 1198
2025
Q3
$1.4M Buy
+155,290
New +$1.36M ﹤0.01% 1587
2025
Q2
Sell
-154,012
Closed -$3.89M 2552
2025
Q1
$3.89M Sell
154,012
-237,720
-61% -$7.06M 0.01% 1017
2024
Q4
$13.5M Sell
391,732
-55,244
-12% -$2.49M 0.03% 599
2024
Q3
$22.1M Buy
446,976
+384,041
+610% +$19.7M 0.06% 388
2024
Q2
$3.79M Buy
62,935
+46,336
+279% +$2.65M 0.01% 924
2024
Q1
$856K Sell
16,599
-227,116
-93% -$11.1M ﹤0.01% 1502
2023
Q4
$9.83M Sell
243,715
-412,230
-63% -$12.1M 0.02% 697
2023
Q3
$18.3M Buy
655,945
+83,502
+15% +$2.49M 0.05% 432
2023
Q2
$16.5M Buy
572,443
+224,275
+64% +$4.99M 0.05% 439
2023
Q1
$5.81M Buy
348,168
+90,468
+35% +$1.28M 0.02% 715
2022
Q4
$3.27M Buy
257,700
+20,059
+8% +$244K 0.01% 851
2022
Q3
$2.85M Buy
+237,641
New +$3.26M 0.01% 852
2022
Q2
Sell
-17,500
Closed -$217K 1612
2022
Q1
$217K Buy
+17,500
New +$210K ﹤0.01% 1059

Other funds holding RXST

Steven Cohen's RXST Position: Q2 2026 in Review

Steven Cohen increased its RxSight (RXST) stake by 6.1% in Q2 2026, buying an estimated $271K and bringing the position to 778,252 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1968.

Steven Cohen first reported a position in RXST in Q1 2022 and has held it in 16 quarters since. The position peaked at $22.1M in Q3 2024. 150 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Steven Cohen held 778,252 shares of RxSight worth $3.75M as of Q2 2026.
  • Steven Cohen bought 44,945 RxSight shares in Q2 2026, an estimated $271K.
  • RxSight made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #1968 holding.
  • Steven Cohen first reported a position in RxSight in Q1 2022 and has held it in 16 quarters since.
  • Steven Cohen's RxSight position peaked at $22.1M in Q3 2024.
  • 150 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.